Sonoma Pharmaceuticals Reports 141% U.S. Revenue Jump and Achieves First-Ever Positive Adjusted EBITDA
Record Revenue Growth and Positive EBITDA Highlight Business Transformation
Sonoma Pharmaceuticals (NASDAQ: SNOA) delivered a landmark first quarter, posting 141% U.S. revenue growth and 60% total revenue growth year-over-year. For the first time in its history, the company reported positive adjusted EBITDA—a major milestone driven by stable costs and surging demand across global markets.
U.S. Revenues Surge on OTC Sales, New Distribution Gains
The company’s first-quarter U.S. revenue soared by $1.4 million to $2.4 million, fueled primarily by rising demand for over-the-counter products and increased activity from both new and existing distributors. Overseas, Europe recorded a 34% revenue boost, in part thanks to favorable exchange rates, while Asia, Latin America, and other regions also contributed to broader growth.
Sonoma’s latest FDA 510(k) clearance for its Microdacyn® Wound Irrigation Solution, which adds expanded claims and packaging, is expected to further widen its U.S. footprint. Additional distribution partnerships in Taiwan, Vietnam, and the United States support the company’s ongoing global expansion goals.
Operating Leverage: Profits Up Despite Flat Expenses
Even as revenues climbed sharply, Sonoma held operating expenses flat at $2.6 million compared to the same quarter last year, demonstrating significant operating leverage. Gross margins improved to 40% (from 36%), and net loss per share narrowed by 88% year-over-year. On a non-GAAP basis, the company achieved a $0.05 million adjusted EBITDA gain, swinging from a loss of $1 million the prior year.
| Key Financial Metric | Q1 2026 | Q1 2025 | % Change |
|---|---|---|---|
| Total Revenue (millions) | $6.41 | $4.02 | +60% |
| Gross Margin | 40% | 36% | +4 pts |
| Operating Expenses (millions) | $2.62 | $2.56 | +2% |
| Adjusted EBITDA (millions) | $0.05 | ($1.00) | +105% |
| Net Loss (millions) | ($0.33) | ($1.24) | -73% |
Global Regulatory Momentum and Distribution Expansion
The recent FDA clearance and new distribution agreements suggest Sonoma’s commercial progress is more than a one-off event. With customers placing larger but less frequent orders internationally—often to capture discounts and cut shipping costs—global revenues could remain lumpy quarter-to-quarter, yet the underlying trend is up. As of June 30, 2026, Sonoma reported a strong cash position with $5.34 million in cash and equivalents, supporting continued expansion and operational flexibility.
What to Watch Next: Strategic Positioning and Market Opportunities
For investors and industry watchers, the ongoing ramp in U.S. sales and international partnerships, combined with momentum from regulatory wins, positions Sonoma as a contender for further profitable growth. Flat expenses amid rising revenue highlight prudent management and a scalable business model.
While broader market uncertainties still apply, Sonoma's recent results mark a dramatic turnaround—and could set the stage for a new growth phase. With additional commercial and regulatory catalysts on the horizon, this quarter may prove to be just the beginning.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI